20
KIT
has entered countries such as the UK, Germany, Italy,
the Netherlands, Denmark, France, Spain and Sweden.
With 14 years of extreme focus and persistence, Medtrum
has rapidly grown to be an innovation leader in diabetes
device industry: the world's smallest and thinnest
tubeless patch pump - the Nano Pump - the first insulin
patch pump fully controlled by a smartphone app; the
first real-time 14-day CGM - Nano CGM - and to be
launched later this year, the first tubeless closed-loop
artificial pancreas system using Medtrum's proprietary
APGO® algorithm.
Taking semiconductor technology and information
technology as a pivot, leveraging the medical device
industry and making millions of diabetic patients to enjoy
better life, this is the original aspiration of Scott Yang,
when he founded the company. As a chronic disease,
diabetes currently cannot be cured and can only be
controlled, which inspired him to found Medtrum, and
to persevere in the face of difficulties. He says, "Diabetes
brings a lot of trouble to people's lives. We hope that
counting on continuous exploration and innovation, we
can make life easier and simpler for people with diabetes.
This is our commitment to diabetes community."
Yang thinks that patients should have better
devices and better user experience, with the benefits
of technological advances and innovation. He firmly
believes that closed-loop artificial pancreas is the
ultimate solution for insulin-dependent people with
diabetes, and that tubeless patch pumps and calibrationfree
CGM are the future. Therefore, from the moment
Medtrum was founded in 2008, the strategy of developing
three products simultaneously: tubeless patch pump,
calibration-free CGM and closed-loop artificial pancreas
system, was employed. Medtrum is the only company in
the world that has insisted on developing the above three
products at the same time since its inception.
Transferring from the semiconductor industry to the
medical device industry, Yang faced some challenges.
In his view, diabetes medical devices are a convergence
of electronics, semiconductor, software, mechanical,
algorithms, chemistry, functional materials - far beyond
the scope of traditional medical tech. He believes that a
multidisciplinary team can break the mould and develop
disruptive technologies, change the business model, and
create unique innovations.
Full range of products
Yang believes that past track record and background
in diabetes device can easily become obstacles to
innovation, so Medtrum's founding team members come
from different industries. Medtrum has always adhered to
a strategy of highly vertical integration and full control of
all key technologies. The tubeless patch pump, CGM and
closed-loop algorithms are all developed in-house. After
years of research and development (R&D) investment,
Medtrum has become an innovative leader in the diabetes
industry. Medtrum is the only company in the diabetes
sector that can offer a full range of products, including
calibration-free continuous glucose monitoring (CGM),
insulin patch pumps and closed loop system algorithms
(artificial pancreas). And these devices are smaller, lighter
and smarter than their competitors.
Unique to Medtrum, the Nano insulin pump and
Nano CGM are designed to be used as standalone
devices, however when hooked together with seamless
integration, users can have the peace of mind with a
Predictive Low Glucose Suspend Function, helping
to prevent periods of hypoglycaemia. Both the Nano
tubeless insulin pump and Nano CGM can be controlled
remotely using your compatible smartphone with the
Medtrum EasyPatch App providing greater convenience
Medtrum's nano-technologuy and smartphone offering.
Medtrum's Nano insulin patch pump..